CSIMarket
 


Atara Biotherapeutics Inc   (ATRA)
Other Ticker:  
 
 

ATRA's Capital Expenditures Growth by Quarter and Year

Atara Biotherapeutics Inc 's Capital Expenditures results by quarter and year




ATRA Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 2.47 0.50 1.49
III Quarter September 0.13 3.86 2.08 0.74
II Quarter June 1.42 2.06 1.33 0.80
I Quarter March 2.61 2.20 2.71 4.17
FY   4.16 10.59 6.62 7.20



ATRA Capital Expenditures third quarter 2022 Y/Y Growth Comment
Atara Biotherapeutics Inc reported drop in Capital Expenditures in the third quarter 2022 by -96.58% to $ 0.13 millions, from the same quarter in 2021.
The fall in the third quarter 2022 Atara Biotherapeutics Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 1069.92%.

Looking into third quarter 2022 results within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Capital Expenditures growth. While Atara Biotherapeutics Inc ' s Capital Expenditures meltdown of -96.58% ranks overall at the positon no. 193 in the third quarter 2022.




ATRA Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 394 % -66.44 % -66.89 %
III Quarter September -96.58 % 85.58 % 181.08 % -90.07 %
II Quarter June -31.07 % 54.89 % 66.25 % -95.96 %
I Quarter March 18.64 % -18.82 % -35.01 % -57.01 %
FY   - 59.97 % -8.06 % -82.63 %

Financial Statements
Atara Biotherapeutics Inc 's third quarter 2022 Capital Expenditures $ 0.13 millions ATRA's Income Statement
Atara Biotherapeutics Inc 's third quarter 2021 Capital Expenditures $ 3.86 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Capital Expenditures Growth >>


ATRA Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -36.01 % -75.96 % 101.35 %
III Quarter September -90.7 % 87.38 % 56.39 % -7.5 %
II Quarter June -45.59 % -6.36 % -50.92 % -80.82 %
I Quarter March 5.67 % 340 % 81.88 % -7.33 %
FY (Year on Year)   - 59.97 % -8.06 % -82.63 %




Capital Expenditures third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #52
Overall #193

Capital Expenditures Y/Y Growth Statistics
High Average Low
17720 % 1069.92 % -95.98 %
(Mar 31 2016)   (Mar 31 2019)
Capital Expenditures third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #52
Overall #193
Capital Expenditures Y/Y Growth Statistics
High Average Low
17720 % 1069.92 % -95.98 %
(Mar 31 2016)   (Mar 31 2019)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Atara Biotherapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 106.05 % -100 %
(Dec 31 2015)  


ATRA's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2022 Atara Biotherapeutics Inc disclosed fall in Capital Expenditures from the previous quarter by -90.7% to $ 0.13 millions, from $ 1.42 millions declared in the previous quarter.

Even periodic factors which commonly elevate III. Quarter 2022 performance, this clearly could not be substantial to recover ATRA's III. Quarter performance, Evelyn Robinson, Biotechnology & Pharmaceuticals industry observer based in Toronto pointed out and wrote that average sequential Capital Expenditures growth is at 106.05% for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 633.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #149
Overall #633
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #149
Overall #633
Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 106.05 % -100 %
(Dec 31 2015)  


ATRA's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2022 Atara Biotherapeutics Inc realized fall in Capital Expenditures sequentially by -90.7% to $ 0.13 millions, from $ 1.42 millions achived in the previous reporting period.

Some seasonal influence were not able to rescue the III. Quarter for the Atara Biotherapeutics Inc , Evelyn Robinson, Biotechnology & Pharmaceuticals industry observer based in Toronto wrote, she voiced little pessimism for the ATRA's direction, she sees further challenges ahead for ATRA and mentioned that average sequential Capital Expenditures growth is at 106.05% for ATRA.

Within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 633.


Atara Biotherapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Capital Expenditures 12 Months Ending $ 6.62 $ 10.35 $ 10.99 $ 10.58 $ 8.62
Y / Y Capital Expenditures Growth (TTM) -23.15 % 51.32 % 79.87 % 59.72 % 13.26 %
Year on Year Capital Expenditures Growth Overall Ranking # 1215 # 2896 # 932 # 1394 # 2394
Seqeuential Capital Expenditures Change (TTM) -35.99 % -5.84 % 3.86 % 22.78 % 26.03 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 302 # 1895 # 1033 # 2122 # 314




Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2022 Atara Biotherapeutics Inc reported a fall in Capital Expenditures by -23.15% year on year, to $7 millions, compare to the 51.32% growth at Jun 30 2022.

In the Healthcare sector 235 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1215, from total ranking in previous quarter at 2896.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
26.03 %
-2.69 %
-39.68 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 236
Overall # 1215

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
13.26 %
-33.61 %
-82.66 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 52
S&P 500 # 302
Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2022 Atara Biotherapeutics Inc reported a fall in Capital Expenditures by -23.15% year on year, to $7 millions, compare to the 51.32% growth at Jun 30 2022.

In the Healthcare sector 235 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1215, from total ranking in previous quarter at 2896.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
26.03 %
-2.69 %
-39.68 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 236
Overall # 1215

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
13.26 %
-33.61 %
-82.66 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 52
S&P 500 # 302




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ATRA's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ATRA's Competitors
Capital Expenditures Growth for Atara Biotherapeutics Inc 's Suppliers
Capital Expenditures Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2022
Tela Bio Inc -0.34%$ -0.344 millions
Edwards Lifesciences Corporation-1.32%$ -1.318 millions
Neuroone Medical Technologies Corporation-1.34%$ -1.337 millions
Guardant Health Inc -1.91%$ -1.910 millions
Seagen Inc -2.56%$ -2.556 millions
Addus Homecare Corporation-3.00%$ -2.999 millions
Concert Pharmaceuticals Inc -3.03%$ -3.030 millions
Merck and Co Inc -3.92%$ -3.925 millions
Precision Optics Corporation Inc -3.93%$ -3.925 millions
Nextcure Inc -4.32%$ -4.317 millions
Electromed Inc -5.19%$ -5.185 millions
Sight Sciences Inc -5.23%$ -5.226 millions
Veracyte inc -5.41%$ -5.408 millions
Baxter International Inc -6.15%$ -6.145 millions
Natera inc -7.06%$ -7.057 millions
Sio Gene Therapies Inc -7.14%$ -7.143 millions
Replimune Group Inc -7.48%$ -7.477 millions
Rockwell Medical inc -7.87%$ -7.874 millions
Harvard Bioscience Inc-7.92%$ -7.917 millions
Bristol myers Squibb Company-8.52%$ -8.519 millions
Davita Inc -8.54%$ -8.535 millions
Dentsply Sirona Inc -8.57%$ -8.571 millions
Sunlink Health Systems Inc -9.83%$ -9.827 millions
Moderna Inc -10.10%$ -10.101 millions
Rhythm Pharmaceuticals inc -10.38%$ -10.377 millions
Sarepta Therapeutics Inc -10.93%$ -10.930 millions
West Pharmaceutical Services Inc -11.49%$ -11.485 millions
Recursion Pharmaceuticals Inc -11.78%$ -11.776 millions
Cytek Biosciences Inc -12.08%$ -12.080 millions
Universal Health Services Inc -12.09%$ -12.089 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com